Maxim Group reissued their buy rating on shares of Dare Bioscience (NASDAQ:DARE) in a research report report published on Thursday, AnalystRatings.com reports. They currently have a $3.00 price target on the biotechnology company’s stock.
“Daré reported 1Q19 with a net loss of ($3M). The company ended the period with $3.5M in cash, though this does not include a $5.2M capital raise (5.26M shares, no warrants) from April. Including the raise, the company has runway until ~1Q20, through multiple catalysts including data from the Post-Coital Test for Ovaprene.”,” the firm’s analyst wrote.
NASDAQ:DARE opened at $0.89 on Thursday. Dare Bioscience has a 1 year low of $0.60 and a 1 year high of $3.25. The company has a market capitalization of $10.18 million, a PE ratio of -0.82 and a beta of 2.20.
A number of hedge funds have recently bought and sold shares of the stock. Renaissance Technologies LLC raised its position in Dare Bioscience by 33.5% in the 1st quarter. Renaissance Technologies LLC now owns 178,346 shares of the biotechnology company’s stock worth $250,000 after purchasing an additional 44,800 shares during the last quarter. Jane Street Group LLC bought a new position in Dare Bioscience in the 1st quarter worth approximately $65,000. Finally, Geode Capital Management LLC raised its position in Dare Bioscience by 80.9% in the 4th quarter. Geode Capital Management LLC now owns 105,470 shares of the biotechnology company’s stock worth $73,000 after purchasing an additional 47,170 shares during the last quarter. Hedge funds and other institutional investors own 6.23% of the company’s stock.
Dare Bioscience Company Profile
Daré Bioscience, Inc, a clinical-stage biopharmaceutical company, focuses on developing and marketing women's reproductive health products in the United States. The company intends to develop therapies in the areas of contraception, vaginal health, sexual health, and fertility. Its product candidates include Ovaprene, a non-hormonal monthly contraceptive; and SST-6007, a topical sildenafil cream for female sexual arousal disorder.
Recommended Story: Price to Earnings Ratio (PE)
Receive News & Ratings for Dare Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dare Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.